[The interaction of monoclonal antibodies to the structural proteins of the Vnukovo-32 vaccinal virus with other viruses of the rabies group]. 1991

S V Gribencha, and O V Vasilenko, and T M Kuz'mitskaia, and V A Furalev, and P G Sveshnikov, and A G Tatarov, and P V Kolotvina, and I F Barinskiĭ

The interaction of 7 monoclonal antibodies (MCA) to the nucleocapsid complex and 3 MCA to protein G of the vaccine virus Vnukovo-32 with 33 and 27 members of the rabies virus group, respectively, was studied. The indirect immunofluorescence test showed 7 MCA to the nucleocapsid complex to recognize 4 antigenic determinants (AD). Two MCA recognized the AD common for all the viruses under study. Individual ecological variants may be detected using other MCA. Three MCA to protein G had marked virus-neutralizing activity. MCA 1C5 neutralized all the rabies viruses under study. The other two MCA differed in the number of viruses they could neutralize. The viruses under study were divided into 4 groups depending on their interactions with certain MCA in neutralization test.

UI MeSH Term Description Entries
D008297 Male Males
D008808 Mice, Inbred CBA An inbred strain of mouse that is widely used in BIOMEDICAL RESEARCH. Mice, CBA,Mouse, CBA,Mouse, Inbred CBA,CBA Mice,CBA Mice, Inbred,CBA Mouse,CBA Mouse, Inbred,Inbred CBA Mice,Inbred CBA Mouse
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D011819 Rabies Vaccines Vaccines or candidate vaccines used to prevent and treat RABIES. The inactivated virus vaccine is used for preexposure immunization to persons at high risk of exposure, and in conjunction with rabies immunoglobulin, for postexposure prophylaxis. Rabies Human Diploid Cell Vaccine,Rabies Vaccine,Vaccine, Rabies,Vaccines, Rabies
D011820 Rabies virus The type species of LYSSAVIRUS causing rabies in humans and other animals. Transmission is mostly by animal bites through saliva. The virus is neurotropic multiplying in neurons and myotubes of vertebrates. Rabies viruses
D005455 Fluorescent Antibody Technique Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (FLUORESCENT ANTIBODY TECHNIQUE, DIRECT) or an indirect method, by formation of antigen-antibody complex which is then labeled with fluorescein-conjugated anti-immunoglobulin antibody (FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT). The tissue is then examined by fluorescence microscopy. Antinuclear Antibody Test, Fluorescent,Coon's Technique,Fluorescent Antinuclear Antibody Test,Fluorescent Protein Tracing,Immunofluorescence Technique,Coon's Technic,Fluorescent Antibody Technic,Immunofluorescence,Immunofluorescence Technic,Antibody Technic, Fluorescent,Antibody Technics, Fluorescent,Antibody Technique, Fluorescent,Antibody Techniques, Fluorescent,Coon Technic,Coon Technique,Coons Technic,Coons Technique,Fluorescent Antibody Technics,Fluorescent Antibody Techniques,Fluorescent Protein Tracings,Immunofluorescence Technics,Immunofluorescence Techniques,Protein Tracing, Fluorescent,Protein Tracings, Fluorescent,Technic, Coon's,Technic, Fluorescent Antibody,Technic, Immunofluorescence,Technics, Fluorescent Antibody,Technics, Immunofluorescence,Technique, Coon's,Technique, Fluorescent Antibody,Technique, Immunofluorescence,Techniques, Fluorescent Antibody,Techniques, Immunofluorescence,Tracing, Fluorescent Protein,Tracings, Fluorescent Protein
D006825 Hybridomas Cells artificially created by fusion of activated lymphocytes with neoplastic cells. The resulting hybrid cells are cloned and produce pure MONOCLONAL ANTIBODIES or T-cell products, identical to those produced by the immunologically competent parent cell. Hybridoma
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000937 Antigen-Antibody Reactions The processes triggered by interactions of ANTIBODIES with their ANTIGENS. Antigen Antibody Reactions,Antigen-Antibody Reaction,Reaction, Antigen-Antibody,Reactions, Antigen-Antibody

Related Publications

S V Gribencha, and O V Vasilenko, and T M Kuz'mitskaia, and V A Furalev, and P G Sveshnikov, and A G Tatarov, and P V Kolotvina, and I F Barinskiĭ
January 1973, Voprosy virusologii,
S V Gribencha, and O V Vasilenko, and T M Kuz'mitskaia, and V A Furalev, and P G Sveshnikov, and A G Tatarov, and P V Kolotvina, and I F Barinskiĭ
January 1975, Voprosy virusologii,
S V Gribencha, and O V Vasilenko, and T M Kuz'mitskaia, and V A Furalev, and P G Sveshnikov, and A G Tatarov, and P V Kolotvina, and I F Barinskiĭ
January 1988, Annales de l'Institut Pasteur. Virology,
S V Gribencha, and O V Vasilenko, and T M Kuz'mitskaia, and V A Furalev, and P G Sveshnikov, and A G Tatarov, and P V Kolotvina, and I F Barinskiĭ
December 1988, Journal of clinical microbiology,
S V Gribencha, and O V Vasilenko, and T M Kuz'mitskaia, and V A Furalev, and P G Sveshnikov, and A G Tatarov, and P V Kolotvina, and I F Barinskiĭ
February 1995, Veterinarni medicina,
S V Gribencha, and O V Vasilenko, and T M Kuz'mitskaia, and V A Furalev, and P G Sveshnikov, and A G Tatarov, and P V Kolotvina, and I F Barinskiĭ
January 1976, Voprosy virusologii,
S V Gribencha, and O V Vasilenko, and T M Kuz'mitskaia, and V A Furalev, and P G Sveshnikov, and A G Tatarov, and P V Kolotvina, and I F Barinskiĭ
April 2014, Monoclonal antibodies in immunodiagnosis and immunotherapy,
S V Gribencha, and O V Vasilenko, and T M Kuz'mitskaia, and V A Furalev, and P G Sveshnikov, and A G Tatarov, and P V Kolotvina, and I F Barinskiĭ
May 1984, Journal of immunology (Baltimore, Md. : 1950),
S V Gribencha, and O V Vasilenko, and T M Kuz'mitskaia, and V A Furalev, and P G Sveshnikov, and A G Tatarov, and P V Kolotvina, and I F Barinskiĭ
January 1994, Archives of virology,
S V Gribencha, and O V Vasilenko, and T M Kuz'mitskaia, and V A Furalev, and P G Sveshnikov, and A G Tatarov, and P V Kolotvina, and I F Barinskiĭ
January 1974, Salud publica de Mexico,
Copied contents to your clipboard!